Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMSW) Non-cash Items (2023 - 2025)

Historic Non-cash Items for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $326.8 million.

  • NewAmsterdam Pharma's Non-cash Items rose 407918.57% to $326.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $326.8 million, marking a year-over-year increase of 407918.57%. This contributed to the annual value of $7.9 million for FY2024, which is 5074.0% up from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Non-cash Items of $326.8 million as of Q3 2025, which was up 407918.57% from $141.1 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Non-cash Items ranged from a high of $326.8 million in Q3 2025 and a low of $5.2 million during Q4 2023
  • Its 3-year average for Non-cash Items is $63.8 million, with a median of $7.9 million in 2024.
  • Within the past 5 years, the most significant YoY rise in NewAmsterdam Pharma's Non-cash Items was 407918.57% (2025), while the steepest drop was 4449.06% (2025).
  • Over the past 3 years, NewAmsterdam Pharma's Non-cash Items (Quarter) stood at $5.2 million in 2023, then skyrocketed by 50.74% to $7.9 million in 2024, then skyrocketed by 4045.06% to $326.8 million in 2025.
  • Its Non-cash Items was $326.8 million in Q3 2025, compared to $141.1 million in Q2 2025 and $8.9 million in Q1 2025.